The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer

被引：0
|
作者：
Xia, Yang [1 ]
Huang, Xiu [1 ]
Jin, Rui [1 ]
Li, Wen [1 ]
Shen, Huahao [1 ]
机构：
[1] Zhejiang Univ, Hangzhou, Peoples R China
来源：
EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷
关键词：
D O I：
10.1183/13993003.congress-2019.PA4669
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA4669
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer
    Poposka, Biljana Ilievska
    Petrusevska, Gordana
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [32] Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine
    Mondaca, Sebastian
    Razavi, Pedram
    Xu, Chongrui
    Offin, Michael
    Myers, Mackenzie
    Scaltriti, Maurizio
    Hechtman, Jaclyn F.
    Bradley, Mikaela
    O'Reilly, Eileen M.
    Berger, Michael F.
    Solit, David B.
    Li, Bob T.
    Abou-Alfa, Ghassan K.
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 9
  • [33] HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer
    Agus, DB
    Bunn, PA
    Franklin, W
    Garcia, M
    Ozols, RF
    SEMINARS IN ONCOLOGY, 2000, 27 (06) : 53 - 63
  • [34] Ado-trastuzumab emtansine in the treatment of lung adenocarcinoma with ERBB2 mutation: a case report and literature review
    Wang, Hao
    He, Yang
    Zhao, Weipeng
    Tong, Zhongsheng
    ANTI-CANCER DRUGS, 2022, 33 (08) : 773 - 777
  • [35] Trastuzumab in the treatment of non-small cell lung cancer
    Azzoli, CG
    Krug, LM
    Miller, VA
    Kris, MG
    Mass, R
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 59 - 65
  • [36] ERBB2mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
    Griguolo, Gaia
    Braso-Maristany, Fara
    Gonzalez-Farre, Blanca
    Pascual, Tomas
    Chic, Nuria
    Sauri, Tamara
    Kates, Ronald
    Gluz, Oleg
    Martinez, Debora
    Pare, Laia
    Tsvetkova, Vassilena
    Pesantez, David
    Vidal, Maria
    Adamo, Barbara
    Munoz, Montserrat
    Galvan, Patricia
    Barbera, Laura
    Cuatrecasas, Miriam
    Christgen, Mathias
    Kreipe, Hans
    Monge-Escartin, Ines
    Villagrasa, Patricia
    Soy, Dolors
    Giarratano, Tommaso
    Dieci, Maria Vittoria
    Conte, Pierfranco
    Harbeck, Nadia
    Guarneri, Valentina
    Prat, Aleix
    CANCERS, 2020, 12 (07) : 1 - 25
  • [37] Ado-trastuzumab emtansine (T-DM1) in HER2+advanced breast cancer patients: does pretreatment with pertuzumab matter?
    Fabi, Alessandra
    Giannarelli, Diana
    Moscetti, Luca
    Santini, Daniele
    Zambelli, Alberto
    De laurentiis, Michelino
    Caruso, Michele
    Generali, Daniele
    Valle, Enrichetta
    Leonardi, Vita
    Cannita, Katia
    Arpino, Grazia
    Filippelli, Gianfranco
    Ferretti, Gianluigi
    Giampaglia, Marianna
    Montemurro, Filippo
    Nistico, Cecilia
    Gasparro, Simona
    Cognetti, Francesco
    FUTURE ONCOLOGY, 2017, 13 (30) : 2791 - 2797
  • [38] Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation
    Mukohara, Toru
    Hosono, Ako
    Mimaki, Sachiyo
    Nakayama, Akiko
    Kusuhara, Shota
    Funasaka, Chikako
    Nakao, Takehiro
    Fukasawa, Yoko
    Kondoh, Chihiro
    Harano, Kenichi
    Naito, Yoichi
    Matsubara, Nobuaki
    Tsuchihara, Katsuya
    Kuwata, Takeshi
    ONCOLOGIST, 2021, 26 (08): : 635 - 639
  • [39] Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer
    Lambert, John M.
    Chari, Ravi V. J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (16) : 6949 - 6964
  • [40] Aberrant methylation in non-small cell lung cancer
    Makoto Suzuki
    Ichiro Yoshino
    Surgery Today, 2010, 40 : 602 - 607
12345